share_log

Dianthus Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.1%),TCG Crossover Fund II, L.P.(5.1%), etc.

Dianthus Therapeutics | SC 13G:超过5%持股股东披露文件-TCG Crossover GP II, LLC(5.1%),TCG Crossover Fund II, L.P.(5.1%)等

美股SEC公告 ·  11/22 16:45
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息